 Protalix BioTherapeutics Inc NYSE: PLX has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April. The FDA issued the response letter for pegunigalsidase alfa PRX-102 in Fabry disease, though no reasons were cited in the letter. 